You are here

  • Home
  • Archive
  • Volume 8, Issue 1
  • Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA1) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD)

Citation Tools

Article menu
Interstitial lung disease
Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA1) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD)

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Corte TJ, Lancaster L, Swigris JJ, et al
Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA1) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD)
BMJ Open Respiratory Research 2021;8:e001026. doi: 10.1136/bmjresp-2021-001026